-
Je něco špatně v tomto záznamu ?
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy
S. D'Sa, J. Khwaja, S. Chow, MA. Dimopoulos, I. Dogliotti, ME. Gatt, R. Hajek, J. Lindsay, G. Merlini, P. Morel, A. Tedeschi, C. Cerchione, M. Leiba, CJ. Patterson, SP. Treon, C. Buske, JV. Matous, M. Varettoni, JMI. Vos, F. Eftimov, MP. Lunn, E....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu konsensus - konference, časopisecké články
- MeSH
- imunoglobulin M * imunologie MeSH
- lidé MeSH
- management nemoci MeSH
- nemoci periferního nervového systému * terapie diagnóza etiologie imunologie MeSH
- Waldenströmova makroglobulinemie * terapie komplikace diagnóza imunologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
The IgM-related peripheral neuropathies (IgM-PN) are a group of chronic disorders characterized by the presence of monoclonal IgM that may be associated with one of several diseases affecting the peripheral nerves. In many cases, there is a monoclonal IgM associated with activity against neural targets, leading to progressive peripheral nerve demyelination. Neurological symptoms in this setting can also result from direct invasion of the peripheral or central nervous system by lymphoplasmacytic cells (neurolymphomatosis and Bing-Neel syndrome respectively) or via other mechanisms (for example AL amyloid deposition or cryoglobulinemic vasculitis). There is an expanding array of treatment options, but high-quality data are sparse. Diagnostic accuracy is important and needs collaboration between hematologists and neuromuscular specialists to determine the sequence and intensity of investigations. Appropriate causal attribution to the IgM disorder is essential to enable the correct therapeutic intervention. The aims of treatment intervention should be clear and realistic. Consistent and clinically meaningful measures are needed to capture treatment success. Despite therapeutic advances, many patients experience persistent disability, highlighting the need for further research.
Centre for Neuromuscular Disease National Hospital for Neurology and Neurosurgery London UK
Colorado Blood Cancer Institute Sarah Cannon Research Institute Denver CO
Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece
Department of Hematology University Hospital of Amiens Amiens France
Department of Neurology Amsterdam UMC Amsterdam The Netherlands
Division of Hematology Fondazione iRCCS Policlinico San Matteo Italy
Institute of Experimental Cancer Research University Hospital Ulm Ulm Germany
Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Unit of Hematology Department of Biotechnology and Health Sciences University of Torino Torino Italy
University College London Hospitals NHS Foundation Trust London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016197
- 003
- CZ-PrNML
- 005
- 20250731091607.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1053/j.seminhematol.2025.04.006 $2 doi
- 035 __
- $a (PubMed)40404484
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a D'Sa, Shirley $u Centre for Waldenström Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: s.d'sa@nhs.net
- 245 10
- $a Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy / $c S. D'Sa, J. Khwaja, S. Chow, MA. Dimopoulos, I. Dogliotti, ME. Gatt, R. Hajek, J. Lindsay, G. Merlini, P. Morel, A. Tedeschi, C. Cerchione, M. Leiba, CJ. Patterson, SP. Treon, C. Buske, JV. Matous, M. Varettoni, JMI. Vos, F. Eftimov, MP. Lunn, E. Kastritis
- 520 9_
- $a The IgM-related peripheral neuropathies (IgM-PN) are a group of chronic disorders characterized by the presence of monoclonal IgM that may be associated with one of several diseases affecting the peripheral nerves. In many cases, there is a monoclonal IgM associated with activity against neural targets, leading to progressive peripheral nerve demyelination. Neurological symptoms in this setting can also result from direct invasion of the peripheral or central nervous system by lymphoplasmacytic cells (neurolymphomatosis and Bing-Neel syndrome respectively) or via other mechanisms (for example AL amyloid deposition or cryoglobulinemic vasculitis). There is an expanding array of treatment options, but high-quality data are sparse. Diagnostic accuracy is important and needs collaboration between hematologists and neuromuscular specialists to determine the sequence and intensity of investigations. Appropriate causal attribution to the IgM disorder is essential to enable the correct therapeutic intervention. The aims of treatment intervention should be clear and realistic. Consistent and clinically meaningful measures are needed to capture treatment success. Despite therapeutic advances, many patients experience persistent disability, highlighting the need for further research.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a management nemoci $7 D019468
- 650 12
- $a imunoglobulin M $x imunologie $7 D007075
- 650 12
- $a nemoci periferního nervového systému $x terapie $x diagnóza $x etiologie $x imunologie $7 D010523
- 650 12
- $a Waldenströmova makroglobulinemie $x terapie $x komplikace $x diagnóza $x imunologie $7 D008258
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Khwaja, Jahanzaib $u Centre for Waldenström Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, UK
- 700 1_
- $a Chow, Signy $u Odette Cancer Centre, Sunnybrook Health Sciences Centre, Division of Medical Oncology and Hematology, Faculty of Medicine, University of Toronto, Toronto, Canada
- 700 1_
- $a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Dogliotti, Irene $u Unit of Hematology, Department of Biotechnology and Health Sciences, University of Torino, Torino, Italy
- 700 1_
- $a Gatt, Moshe E $u Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel
- 700 1_
- $a Hajek, Roman $u Department of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Lindsay, Jindriska $u University College London Hospitals, NHS Foundation Trust, London, UK
- 700 1_
- $a Merlini, Giampaolo $u Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
- 700 1_
- $a Morel, Pierre $u Department of Hematology, University Hospital of Amiens, Amiens, France
- 700 1_
- $a Tedeschi, Alessandra $u Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Cerchione, Claudio $u Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 700 1_
- $a Leiba, Merav $u Assuta Ashdod University Hospital, Faculty of Health Sciences, Ben-Gurion University of the Negev, Jerusalem, Israel
- 700 1_
- $a Patterson, Christopher J $u Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
- 700 1_
- $a Treon, Steven P $u Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
- 700 1_
- $a Buske, Christian $u Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
- 700 1_
- $a Matous, Jeffrey V $u Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO
- 700 1_
- $a Varettoni, Marzia $u Division of Hematology, Fondazione iRCCS Policlinico, San Matteo, Italy
- 700 1_
- $a Vos, Josephine M I $u Department of Hematology, Cancer Center Amsterdam/LYMMCARE, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Eftimov, Filip $u Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands
- 700 1_
- $a Lunn, Michael P $u Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London UK
- 700 1_
- $a Kastritis, Efstathios $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
- 773 0_
- $w MED00004323 $t Seminars in hematology $x 1532-8686 $g Roč. 62, č. 2 (2025), s. 76-84
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40404484 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091602 $b ABA008
- 999 __
- $a ok $b bmc $g 2366795 $s 1253322
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 62 $c 2 $d 76-84 $e 20250502 $i 1532-8686 $m Seminars in hematology $n Semin Hematol $x MED00004323
- LZP __
- $a Pubmed-20250708
